Digital health and sales veteran Bryan Humbarger joins cardiac health AI innovator at key growth inflection point
OAKLAND, Calif.–(BUSINESS WIRE)–Eko today announced the appointment of digital health sales veteran Bryan Humbarger to the position of Senior Vice President, Commercial. In this role, Mr. Humbarger will oversee sales and commercial operations for Eko’s AI and telemedicine software platforms for health systems, practices and providers worldwide.
Mr. Humbarger most recently served as Vice President of Sales at cardiac digital health companies AliveCor and Heartflow. Previously, he spent nearly two decades gaining sales experience at medical device and technology companies, including Medtronic and Bioquell.
“Bryan’s leadership skills, proven ability to drive growth and passion for improving cardiac health will be key assets as Eko continues to expand adoption of our AI and telemedicine solutions,” said Connor Landgraf, CEO and co-founder of Eko. “Now more than ever, telemedicine is playing a critical role in caring for patients and Bryan will play a pivotal part in scaling operations for the company’s next phase of growth and continued expansion.”
Mr. Humbarger joins Eko following the achievement of several key company milestones, including the clearance of its cardiac AI algorithms by the U.S. Food and Drug Administration and the launch of Eko’s AI-powered telehealth platform.
“Eko’s next generation of cardiac and pulmonary solutions are already making a difference for providers and their patients, and I am thrilled to bring my experience in cardiology and digital health to further accelerate the adoption of Eko’s technology,” said Mr. Humbarger. “Being at the forefront of delivering what’s next in cardiovascular care is my passion, and I am thrilled to continue this journey at Eko, a company making a difference in how cardiac and pulmonary care is delivered.”
About Eko
Eko is elevating the way clinicians detect and monitor cardiac and respiratory disease by bringing together advanced sensors, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by tens of thousands of clinicians treating millions of patients around the world, in-person, and through telehealth. The company is headquartered in Oakland, California and privately held, with investments from ARTIS Ventures, NTT Venture Capital, DigiTx Ventures, Mayo Clinic, Sutter Health and others.
For more information, visit www.ekohealth.com.
Contacts
MacDougall
Lauren Arnold
larnold@macbiocom.com
+1 (781) 235-3060
